Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
For Research Purposes Only
Out of StockCJC-1295 with DAC
Third-Party TestedPurity Standards
Total
$29.99Size
Quantity
1
Bundle & Save
Molecular Profile
Molecular Profile
Type
Synthetic peptide (tetrasubstituted GRF(1-29) sequence, 30 residues, with an albumin-binding DAC group)
Molecular formula
C165H269N47O46
Molecular weight
~3,647 g/mol
CAS number
863288-34-0
Amino acids
30
Sequence
H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-NH2 (Nε-3-maleimidopropionyl on the C-terminal Lys30)
Modification
Four substitutions relative to GRF(1-29) — D-Ala2, Gln8, Ala15, Leu27 — conferring resistance to dipeptidyl peptidase-4 and other plasma proteases; C-terminal amidation; and an Nε-3-maleimidopropionyl-Lys30 (DAC) linker whose maleimide forms a covalent thioether bond with cysteine-34 of serum albumin.
Mechanism & Target Class
Mechanism & Target Class
A 30-residue synthetic peptide corresponding to a tetrasubstituted GRF(1-29) sequence — an N-terminal fragment analog of a 44-residue hypothalamic peptide. Class B / secretin-family GPCRs of this family comprise an extracellular domain and a seven-transmembrane bundle, and cryo-EM studies of the family resolve the canonical two-domain binding mode in which the peptide N-terminus inserts into the transmembrane bundle while the C-terminal segment is held by the extracellular domain. Two structural features distinguish the molecule: a tetrasubstituted GRF(1-29) backbone (D-Ala2, Gln8, Ala15, Leu27) that resists protease cleavage, and a Drug Affinity Complex — an Nε-maleimidopropionyl-lysine appended at the C-terminus whose maleimide reacts with the free thiol on cysteine-34 of serum albumin, converting the peptide into a long-circulating albumin conjugate.
Storage & Handling
Storage & Handling
Lyophilized
20°C
protected from light and moisture; frozen for longer-term storage.
As a peptide, susceptible to degradation from heat, light, moisture, and repeated freeze-thaw. The DAC maleimide group is thiol-reactive. Research-use-only; not for human or veterinary use.
References
References
Reviews
- 1
Memdouh S, et al. (2021). Drug Test Anal
- 2
Sinha DK, et al. (2020). Transl Androl Urol
Reviews
- 3
Sigalos JT, Pastuszak AW. (2018). Sex Med Rev
- 4
Pal K, et al. (2012). Acta Pharmacol Sin
- 5
Halmos G, et al. (2023). Vitam Horm
- 6
Halmos G, et al. (2025). Rev Endocr Metab Disord
- 7
Bioletto F, et al. (2025). Rev Endocr Metab Disord
- 8
Caspersen MB, et al. (2017). Ther Deliv
Clinical
- 9
Teichman SL, et al. (2006). J Clin Endocrinol Metab
- 10
Ionescu M, Frohman LA. (2006). J Clin Endocrinol Metab
- 11
ClinicalTrials.gov registry. ClinicalTrials.gov
Primary research
- 12
Zhou F, et al. (2020). Nat Commun
- 13
Timms M, et al. (2019). Drug Test Anal
- 14
Knoop A, et al. (2016). Anal Bioanal Chem
- 15
Henninge J, et al. (2010). Drug Test Anal
- 16
Sackmann-Sala L, et al. (2009). Growth Horm IGF Res
- 17
Alba M, et al. (2006). Am J Physiol Endocrinol Metab
- 18
Jetté L, et al. (2005). Endocrinology
- 19
Timms M, et al. (2019). Drug Test Anal
- 20
Matsoukas MT, Spyroulias GA. (2017). Mol Biosyst
- 21
Uçaktürk E, Nemutlu E. (2026). J Pharm Biomed Anal
Primary Database
Primary Database
Also known as: CJC-1295 DAC, Mod GRF 1-29 (non-DAC variant)
View this compound in the Research Library →Research Use Only. All products sold by Luvaminos are intended solely for in vitro research and laboratory use by qualified professionals. They are not approved by the FDA and are not intended for human or animal consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm you are a licensed researcher or institution and accept full responsibility for compliance with all applicable laws and regulations.
